Here, we demonstrate that in nelarabine-resistant T-ALL cell lines, there is a hyperactivation of PI3K/AKT/mTOR, ERK1/2 and Bcl2 signaling in response to nelarabine. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.